Surf Therapeutics

About 2.5 million Americans are intolerant to or do not achieve remission with the currently available therapies. This leads to chronic pain, disability, and decreased longevity. The company is developing an at-home therapy device that can safely and effectively induce an anti-inflammatory effect to treat these patients.

Completed first in human study yielding very positive outcomes with statistically significant reduction in primary outcomes in treatment group vs sham group.

• 
  Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins

  BioSpace · Mar 18, 2026

• 
  Surf Therapeutics Extends Seed Funding; Raises $6M in Total

  FinSMEs · Mar 17, 2026

  Surf Therapeutics, an Austin, TX-based clinical-stage company developing non-invasive ultrasound neuromodulation therapies, raised an undisclosed amount in Seed expansion funding